JP2022501381A

JP2022501381A - 筋萎縮性側索硬化症の治療方法

筋萎縮性側索硬化症の治療方法 Download PDF

Info

Publication number: JP2022501381A
Authority: JP; Japan
Prior art keywords: als; sulfate; palmitoyl; mice; sod1
Prior art date: 2018-09-20
Legal status : Pending

Application number

JP2021515595A

Other languages

English (en)

Japanese (ja)

Other versions

JPWO2020058979A5 (zh

Inventor

エランエリナヴ，

エランセガル，

Current Assignee

Yeda Research and Development Co Ltd

Original Assignee

Yeda Research and Development Co Ltd

Priority date

2018-09-20

Filing date

2019-09-19

Publication date

2022-01-06

2018-09-20 Priority claimed from IL261908A external-priority patent/IL261908A/en

2019-06-27 Priority claimed from IL26775219A external-priority patent/IL267752A/en

2019-09-19 Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd

2022-01-06 Publication of JP2022501381A publication Critical patent/JP2022501381A/ja

2022-09-27 Publication of JPWO2020058979A5 publication Critical patent/JPWO2020058979A5/ja

Status Pending legal-status Critical Current

Links

206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims description 211
238000000034 method Methods 0.000 claims abstract description 112
239000002207 metabolite Substances 0.000 claims abstract description 105
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 154
241000702462 Akkermansia muciniphila Species 0.000 claims description 134
230000001580 bacterial effect Effects 0.000 claims description 120
244000005700 microbiome Species 0.000 claims description 99
238000011282 treatment Methods 0.000 claims description 76
241000736262 Microbiota Species 0.000 claims description 52
239000011570 nicotinamide Substances 0.000 claims description 47
229960003966 nicotinamide Drugs 0.000 claims description 47
235000005152 nicotinamide Nutrition 0.000 claims description 47
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 42
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims description 40
238000004458 analytical method Methods 0.000 claims description 39
241000894006 Bacteria Species 0.000 claims description 38
239000003795 chemical substances by application Substances 0.000 claims description 38
-1 cisgri Chemical compound 0.000 claims description 38
230000000694 effects Effects 0.000 claims description 33
230000000813 microbial effect Effects 0.000 claims description 33
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 31
ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims description 30
241001464870 [Ruminococcus] torques Species 0.000 claims description 29
235000019126 equol Nutrition 0.000 claims description 29
230000000968 intestinal effect Effects 0.000 claims description 29
IESVDEZGAHUQJU-ZLBXKVHBSA-N 1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC IESVDEZGAHUQJU-ZLBXKVHBSA-N 0.000 claims description 28
ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims description 27
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 26
241000192031 Ruminococcus Species 0.000 claims description 24
CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 claims description 22
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 21
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 21
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
229940076279 serotonin Drugs 0.000 claims description 21
229930195712 glutamate Natural products 0.000 claims description 20
229960004559 theobromine Drugs 0.000 claims description 20
241000160321 Parabacteroides Species 0.000 claims description 19
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 19
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical group CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 19
229960003415 propylparaben Drugs 0.000 claims description 19
229960004418 trolamine Drugs 0.000 claims description 19
241001464948 Coprococcus Species 0.000 claims description 17
229940114081 cinnamate Drugs 0.000 claims description 16
244000005709 gut microbiome Species 0.000 claims description 16
GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 claims description 14
229940039696 lactobacillus Drugs 0.000 claims description 14
108010036504 phenylalanylglycine Proteins 0.000 claims description 14
239000006041 probiotic Substances 0.000 claims description 14
235000018291 probiotics Nutrition 0.000 claims description 14
WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 14
WPAMZTWLKIDIOP-UCORVYFPSA-N 2-keto-3-deoxy-L-galactonic acid Chemical compound OC[C@H](O)[C@@H](O)CC(=O)C(O)=O WPAMZTWLKIDIOP-UCORVYFPSA-N 0.000 claims description 13
241001584951 Anaerostipes hadrus Species 0.000 claims description 13
241000692822 Bacteroidales Species 0.000 claims description 13
241001134772 Bifidobacterium pseudocatenulatum Species 0.000 claims description 13
241000588724 Escherichia coli Species 0.000 claims description 13
241001112693 Lachnospiraceae Species 0.000 claims description 13
241000186660 Lactobacillus Species 0.000 claims description 13
RWKUXQNLWDTSLO-GWQJGLRPSA-N N-hexadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC RWKUXQNLWDTSLO-GWQJGLRPSA-N 0.000 claims description 13
LKQLRGMMMAHREN-YJFXYUILSA-N N-stearoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC LKQLRGMMMAHREN-YJFXYUILSA-N 0.000 claims description 13
241000194017 Streptococcus Species 0.000 claims description 13
241001531197 [Eubacterium] hallii Species 0.000 claims description 13
241001531188 [Eubacterium] rectale Species 0.000 claims description 13
NPDSHTNEKLQQIJ-ZJHFMPGASA-N alpha-dimorphecolic acid Chemical compound CCCCC\C=C/C=C/C(O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-ZJHFMPGASA-N 0.000 claims description 13
239000003242 anti bacterial agent Substances 0.000 claims description 13
KFDHKOFCRYUXLA-UHFFFAOYSA-N chavicol hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=C(CC=C)C=C1 KFDHKOFCRYUXLA-UHFFFAOYSA-N 0.000 claims description 13
150000001982 diacylglycerols Chemical class 0.000 claims description 13
NPDSHTNEKLQQIJ-UHFFFAOYSA-N dimorphecolic acid Natural products CCCCCC=CC=CC(O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-UHFFFAOYSA-N 0.000 claims description 13
229940114119 gentisate Drugs 0.000 claims description 13
230000009467 reduction Effects 0.000 claims description 13
HNICUWMFWZBIFP-BSZOFBHHSA-N 13-HODE Chemical compound CCCCCC(O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-BSZOFBHHSA-N 0.000 claims description 12
241001220441 Bacteroides plebeius Species 0.000 claims description 12
241001531192 Eubacterium ventriosum Species 0.000 claims description 12
241000605980 Faecalibacterium prausnitzii Species 0.000 claims description 12
241000872832 Roseburia hominis Species 0.000 claims description 12
241001464867 [Ruminococcus] gnavus Species 0.000 claims description 12
BNOCVKCSBKRYHN-UHFFFAOYSA-N 2-aminophenol;sulfuric acid Chemical compound OS(O)(=O)=O.NC1=CC=CC=C1O BNOCVKCSBKRYHN-UHFFFAOYSA-N 0.000 claims description 11
241000604451 Acidaminococcus Species 0.000 claims description 11
241000606124 Bacteroides fragilis Species 0.000 claims description 11
241000186020 Bifidobacterium dentium Species 0.000 claims description 11
241001443867 Catenibacterium mitsuokai Species 0.000 claims description 11
241000186588 Erysipelatoclostridium ramosum Species 0.000 claims description 11
241000604449 Megasphaera Species 0.000 claims description 11
CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 claims description 11
JSJWCHRYRHKBBW-UHFFFAOYSA-N N-carbamoyl-beta-alanine Chemical compound NC(=O)NCCC(O)=O JSJWCHRYRHKBBW-UHFFFAOYSA-N 0.000 claims description 11
241000260425 Parasutterella excrementihominis Species 0.000 claims description 11
YEIQSAXUPKPPBN-UHFFFAOYSA-N Phenylpropionylglycine Chemical compound OC(=O)CNC(=O)CCC1=CC=CC=C1 YEIQSAXUPKPPBN-UHFFFAOYSA-N 0.000 claims description 11
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 11
241000194008 Streptococcus anginosus Species 0.000 claims description 11
241001147795 Tyzzerella nexilis Species 0.000 claims description 11
241001246487 [Clostridium] bolteae Species 0.000 claims description 11
241000186569 [Clostridium] leptum Species 0.000 claims description 11
230000003115 biocidal effect Effects 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
210000000936 intestine Anatomy 0.000 claims description 11
229960001682 n-acetyltyrosine Drugs 0.000 claims description 11
229910021653 sulphate ion Inorganic materials 0.000 claims description 11
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims description 11
241000823281 Burkholderiales bacterium Species 0.000 claims description 10
241001248432 Helicobacteraceae Species 0.000 claims description 10
241000605861 Prevotella Species 0.000 claims description 10
241000731710 Allobaculum Species 0.000 claims description 9
241000204018 Anaeroplasma Species 0.000 claims description 9
241000692845 Rikenellaceae Species 0.000 claims description 9
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 9
229940079593 drug Drugs 0.000 claims description 9
241000606125 Bacteroides Species 0.000 claims description 8
241000226559 Candidatus Arthromitus Species 0.000 claims description 8
241001134569 Flavonifractor plautii Species 0.000 claims description 8
241000202985 Methanobrevibacter smithii Species 0.000 claims description 8
AQTYXAPIHMXAAV-UHFFFAOYSA-N O-methoxycatechol-O-sulphate Chemical compound COC1=CC=CC=C1OS(O)(=O)=O AQTYXAPIHMXAAV-UHFFFAOYSA-N 0.000 claims description 8
241000843248 Oscillibacter Species 0.000 claims description 8
241000266824 Oscillospira Species 0.000 claims description 8
241001136694 Subdoligranulum Species 0.000 claims description 8
230000000529 probiotic effect Effects 0.000 claims description 8
LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
241000186000 Bifidobacterium Species 0.000 claims description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
241001430149 Clostridiaceae Species 0.000 claims description 5
241001657523 Coriobacteriaceae Species 0.000 claims description 5
241000123710 Sutterella Species 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 5
229930182480 glucuronide Natural products 0.000 claims description 5
BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims description 5
241000701474 Alistipes Species 0.000 claims description 4
FHQVHHIBKUMWTI-OTMQOFQLSA-N {1-hexadecanoyl-2-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}ethanolamine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC FHQVHHIBKUMWTI-OTMQOFQLSA-N 0.000 claims description 4
CXISPYVYMQWFLE-UHFFFAOYSA-N alanylglycine Chemical compound CC(N)C(=O)NCC(O)=O CXISPYVYMQWFLE-UHFFFAOYSA-N 0.000 claims description 3
108010047495 alanylglycine Proteins 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
125000000405 phenylalanyl group Chemical group 0.000 claims description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
229960001867 guaiacol Drugs 0.000 claims description 2
241001515965 unidentified phage Species 0.000 claims description 2
FPXPQMOQWJZYBL-UHFFFAOYSA-N quinol sulfate Chemical compound OC1=CC=C(OS(O)(=O)=O)C=C1 FPXPQMOQWJZYBL-UHFFFAOYSA-N 0.000 claims 5
239000004471 Glycine Substances 0.000 claims 1
BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 claims 1
230000007269 microbial metabolism Effects 0.000 claims 1
238000010586 diagram Methods 0.000 abstract description 3
241000699670 Mus sp. Species 0.000 description 221
241000894007 species Species 0.000 description 78
108090000623 proteins and genes Proteins 0.000 description 71
239000000203 mixture Substances 0.000 description 60
238000012360 testing method Methods 0.000 description 38
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
239000000523 sample Substances 0.000 description 37
108020004414 DNA Proteins 0.000 description 34
208000024891 symptom Diseases 0.000 description 34
201000010099 disease Diseases 0.000 description 31
108091033409 CRISPR Proteins 0.000 description 30
210000002161 motor neuron Anatomy 0.000 description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
238000010354 CRISPR gene editing Methods 0.000 description 25
238000002474 experimental method Methods 0.000 description 25
238000000585 Mann–Whitney U test Methods 0.000 description 24
229910001868 water Inorganic materials 0.000 description 24
241000699666 Mus <mouse, genus> Species 0.000 description 22
230000000926 neurological effect Effects 0.000 description 22
238000012163 sequencing technique Methods 0.000 description 22
210000002966 serum Anatomy 0.000 description 21
108020004465 16S ribosomal RNA Proteins 0.000 description 20
210000001175 cerebrospinal fluid Anatomy 0.000 description 18
239000012634 fragment Substances 0.000 description 18
239000003981 vehicle Substances 0.000 description 18
108091028043 Nucleic acid sequence Proteins 0.000 description 17
210000004027 cell Anatomy 0.000 description 17
230000006870 function Effects 0.000 description 17
235000018102 proteins Nutrition 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
230000004083 survival effect Effects 0.000 description 17
239000004480 active ingredient Substances 0.000 description 16
210000003205 muscle Anatomy 0.000 description 16
239000008194 pharmaceutical composition Substances 0.000 description 16
239000000047 product Substances 0.000 description 16
238000011002 quantification Methods 0.000 description 16
230000001105 regulatory effect Effects 0.000 description 16
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
150000001875 compounds Chemical class 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 14
210000000278 spinal cord Anatomy 0.000 description 14
230000015572 biosynthetic process Effects 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
235000013305 food Nutrition 0.000 description 12
230000004060 metabolic process Effects 0.000 description 12
238000010172 mouse model Methods 0.000 description 12
102000004196 processed proteins & peptides Human genes 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 11
241000186606 Lactobacillus gasseri Species 0.000 description 11
241001135223 Prevotella melaninogenica Species 0.000 description 11
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 11
230000002550 fecal effect Effects 0.000 description 11
238000002705 metabolomic analysis Methods 0.000 description 11
230000001431 metabolomic effect Effects 0.000 description 11
210000003097 mucus Anatomy 0.000 description 11
239000002773 nucleotide Substances 0.000 description 11
125000003729 nucleotide group Chemical group 0.000 description 11
230000037361 pathway Effects 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
108020005004 Guide RNA Proteins 0.000 description 10
230000014509 gene expression Effects 0.000 description 10
230000012010 growth Effects 0.000 description 10
230000009469 supplementation Effects 0.000 description 10
208000027244 Dysbiosis Diseases 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
241000606210 Parabacteroides distasonis Species 0.000 description 9
229940088710 antibiotic agent Drugs 0.000 description 9
239000000872 buffer Substances 0.000 description 9
230000007140 dysbiosis Effects 0.000 description 9
229940088598 enzyme Drugs 0.000 description 9
238000009472 formulation Methods 0.000 description 9
238000002595 magnetic resonance imaging Methods 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
238000005259 measurement Methods 0.000 description 9
230000007659 motor function Effects 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
230000009885 systemic effect Effects 0.000 description 9
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
102000008221 Superoxide Dismutase-1 Human genes 0.000 description 8
108010021188 Superoxide Dismutase-1 Proteins 0.000 description 8
210000003169 central nervous system Anatomy 0.000 description 8
235000015872 dietary supplement Nutrition 0.000 description 8
238000012417 linear regression Methods 0.000 description 8
230000033001 locomotion Effects 0.000 description 8
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
229910052757 nitrogen Inorganic materials 0.000 description 8
FPXPQMOQWJZYBL-UHFFFAOYSA-M quinol sulfate(1-) Chemical compound OC1=CC=C(OS([O-])(=O)=O)C=C1 FPXPQMOQWJZYBL-UHFFFAOYSA-M 0.000 description 8
239000000725 suspension Substances 0.000 description 8
206010003694 Atrophy Diseases 0.000 description 7
241000030714 Parabacteroides goldsteinii Species 0.000 description 7
230000037444 atrophy Effects 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
210000001072 colon Anatomy 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
238000003745 diagnosis Methods 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
235000013376 functional food Nutrition 0.000 description 7
238000001325 log-rank test Methods 0.000 description 7
230000037353 metabolic pathway Effects 0.000 description 7
230000004770 neurodegeneration Effects 0.000 description 7
150000005480 nicotinamides Chemical class 0.000 description 7
230000000750 progressive effect Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
108010077805 Bacterial Proteins Proteins 0.000 description 6
229920002307 Dextran Polymers 0.000 description 6
206010061818 Disease progression Diseases 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
208000001308 Fasciculation Diseases 0.000 description 6
241000282412 Homo Species 0.000 description 6
108091028113 Trans-activating crRNA Proteins 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
230000027455 binding Effects 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
230000005750 disease progression Effects 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
230000003204 osmotic effect Effects 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
230000008569 process Effects 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
239000013598 vector Substances 0.000 description 6
241000186871 Lactobacillus murinus Species 0.000 description 5
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 5
102000000524 Nuclear Respiratory Factor 1 Human genes 0.000 description 5
108010016592 Nuclear Respiratory Factor 1 Proteins 0.000 description 5
238000011529 RT qPCR Methods 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
238000003556 assay Methods 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
238000012937 correction Methods 0.000 description 5
230000007423 decrease Effects 0.000 description 5
230000007850 degeneration Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
210000003128 head Anatomy 0.000 description 5
230000006872 improvement Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000000463 material Substances 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
238000012545 processing Methods 0.000 description 5
210000000813 small intestine Anatomy 0.000 description 5
230000002269 spontaneous effect Effects 0.000 description 5
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
241001443880 Coprobacillus cateniformis Species 0.000 description 4
241001657508 Eggerthella lenta Species 0.000 description 4
230000005526 G1 to G0 transition Effects 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
101000693844 Homo sapiens Insulin-like growth factor-binding protein complex acid labile subunit Proteins 0.000 description 4
208000007101 Muscle Cramp Diseases 0.000 description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
238000010171 animal model Methods 0.000 description 4
239000011324 bead Substances 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000001851 biosynthetic effect Effects 0.000 description 4
230000006696 biosynthetic metabolic pathway Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
235000013365 dairy product Nutrition 0.000 description 4
238000004925 denaturation Methods 0.000 description 4
230000036425 denaturation Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000008298 dragée Substances 0.000 description 4
229960003276 erythromycin Drugs 0.000 description 4
230000007717 exclusion Effects 0.000 description 4
238000000605 extraction Methods 0.000 description 4
210000003608 fece Anatomy 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
206010020745 hyperreflexia Diseases 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
208000005264 motor neuron disease Diseases 0.000 description 4
229950006238 nadide Drugs 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000040430 polynucleotide Human genes 0.000 description 4
108091033319 polynucleotide Proteins 0.000 description 4
239000002157 polynucleotide Substances 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000012552 review Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
239000003643 water by type Substances 0.000 description 4
108020004463 18S ribosomal RNA Proteins 0.000 description 3
208000000187 Abnormal Reflex Diseases 0.000 description 3
208000019901 Anxiety disease Diseases 0.000 description 3
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
241001657509 Eggerthella Species 0.000 description 3
102100031780 Endonuclease Human genes 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
101150058357 Muc2 gene Proteins 0.000 description 3
206010056677 Nerve degeneration Diseases 0.000 description 3
240000007594 Oryza sativa Species 0.000 description 3
235000007164 Oryza sativa Nutrition 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
208000005392 Spasm Diseases 0.000 description 3
241001580973 Subdoligranulum variabile Species 0.000 description 3
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000036506 anxiety Effects 0.000 description 3
230000006399 behavior Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000007329 chopped meat medium Substances 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
230000006866 deterioration Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000002222 downregulating effect Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
210000004744 fore-foot Anatomy 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000030279 gene silencing Effects 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
230000035859 hyperreflexia Effects 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
201000010901 lateral sclerosis Diseases 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
229960000282 metronidazole Drugs 0.000 description 3
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
230000002981 neuropathic effect Effects 0.000 description 3
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000012175 pyrosequencing Methods 0.000 description 3
108700022487 rRNA Genes Proteins 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
235000009566 rice Nutrition 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 2
LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 2
JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
241000702460 Akkermansia Species 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
241000606215 Bacteroides vulgatus Species 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000283707 Capra Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
206010010264 Condition aggravated Diseases 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
208000019505 Deglutition disease Diseases 0.000 description 2
241001269524 Dura Species 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241001438869 Eisenbergiella tayi Species 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
108700039887 Essential Genes Proteins 0.000 description 2
101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
241000202987 Methanobrevibacter Species 0.000 description 2
108700011259 MicroRNAs Proteins 0.000 description 2
108700005443 Microbial Genes Proteins 0.000 description 2
208000026072 Motor neurone disease Diseases 0.000 description 2
101000693855 Mus musculus Insulin-like growth factor-binding protein complex acid labile subunit Proteins 0.000 description 2
206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
208000032319 Primary lateral sclerosis Diseases 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 2
238000003559 RNA-seq method Methods 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
108091027544 Subgenomic mRNA Proteins 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 2
108010059993 Vancomycin Proteins 0.000 description 2
102000044820 Zonula Occludens-1 Human genes 0.000 description 2
108700007340 Zonula Occludens-1 Proteins 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000001133 acceleration Effects 0.000 description 2
239000002253 acid Substances 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
229960003022 amoxicillin Drugs 0.000 description 2
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
230000003698 anagen phase Effects 0.000 description 2
238000000137 annealing Methods 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
235000013361 beverage Nutrition 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
235000013877 carbamide Nutrition 0.000 description 2
YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000001364 causal effect Effects 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
229940106164 cephalexin Drugs 0.000 description 2
AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 2
235000013351 cheese Nutrition 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
230000003920 cognitive function Effects 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000012350 deep sequencing Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
230000002638 denervation Effects 0.000 description 2
238000004807 desolvation Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
239000000975 dye Substances 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
238000000132 electrospray ionisation Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
230000006862 enzymatic digestion Effects 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
230000037406 food intake Effects 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000003304 gavage Methods 0.000 description 2
230000036541 health Effects 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
238000007489 histopathology method Methods 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000010191 image analysis Methods 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
238000003368 label free method Methods 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
KTHADMDGDNYQRX-UHFFFAOYSA-N methyl (indol-3-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OC)=CNC2=C1 KTHADMDGDNYQRX-UHFFFAOYSA-N 0.000 description 2
239000002679 microRNA Substances 0.000 description 2
239000013586 microbial product Substances 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
230000002438 mitochondrial effect Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
238000010606 normalization Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
230000036407 pain Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000035699 permeability Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000003753 real-time PCR Methods 0.000 description 2
230000008844 regulatory mechanism Effects 0.000 description 2
230000003252 repetitive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000004202 respiratory function Effects 0.000 description 2
102220020162 rs397508045 Human genes 0.000 description 2
238000007480 sanger sequencing Methods 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000007940 sugar coated tablet Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000009966 trimming Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
229960003165 vancomycin Drugs 0.000 description 2
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
229960001600 xylazine Drugs 0.000 description 2
235000013618 yogurt Nutrition 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
LMXZOKNDMCWYON-HZJYTTRNSA-N (12z,15z)-1,2,3-trihydroxyhenicosa-12,15-dien-4-one Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)C(O)C(O)CO LMXZOKNDMCWYON-HZJYTTRNSA-N 0.000 description 1
SDOFMBGMRVAJNF-KVTDHHQDSA-N (2r,3r,4r,5r)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-KVTDHHQDSA-N 0.000 description 1
WHUUTDBJXJRKMK-OKGZFLLSSA-N (2s)-2,3,3-trideuterio-2-(dideuterioamino)pentanedioic acid Chemical compound [2H]N([2H])[C@]([2H])(C(O)=O)C([2H])([2H])CC(O)=O WHUUTDBJXJRKMK-OKGZFLLSSA-N 0.000 description 1
NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 description 1
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
NNULBSISHYWZJU-KPLGQKMUSA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-KPLGQKMUSA-N 0.000 description 1
KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
BFNMZJQMWPPBKE-UHFFFAOYSA-N 1-oxo-3h-2-benzofuran-4-carbonitrile Chemical compound C1=CC=C(C#N)C2=C1C(=O)OC2 BFNMZJQMWPPBKE-UHFFFAOYSA-N 0.000 description 1
CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
VSTZVCJQGSLNLL-UHFFFAOYSA-N 2-aminophenyl hydrogen sulfate Chemical compound NC1=CC=CC=C1OS(O)(=O)=O VSTZVCJQGSLNLL-UHFFFAOYSA-N 0.000 description 1
ZMZQVAUJTDKQGE-UHFFFAOYSA-N 2-ethylhydracrylic acid Chemical compound CCC(CO)C(O)=O ZMZQVAUJTDKQGE-UHFFFAOYSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
102100026936 2-oxoglutarate dehydrogenase, mitochondrial Human genes 0.000 description 1
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
CQNPVMCASGWEHM-UHFFFAOYSA-N 3-[4-(dimethylamino)phenyl]prop-2-enoic acid Chemical compound CN(C)C1=CC=C(C=CC(O)=O)C=C1 CQNPVMCASGWEHM-UHFFFAOYSA-N 0.000 description 1
GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
239000001647 3-phenylprop-2-enyl 2-methylpropanoate Substances 0.000 description 1
239000001128 3-phenylprop-2-enyl benzoate Substances 0.000 description 1
239000001623 3-phenylprop-2-enyl formate Substances 0.000 description 1
MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
ZLWYEPMDOUQDBW-UHFFFAOYSA-N 6-aminonicotinamide Chemical compound NC(=O)C1=CC=C(N)N=C1 ZLWYEPMDOUQDBW-UHFFFAOYSA-N 0.000 description 1
101710110983 Abaecin Proteins 0.000 description 1
206010000117 Abnormal behaviour Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
101100383830 Akkermansia muciniphila (strain ATCC BAA-835 / DSM 22959 / JCM 33894 / BCRC 81048 / CCUG 64013 / CIP 107961 / Muc) Amuc_0430 gene Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
108700023418 Amidases Proteins 0.000 description 1
108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101710107631 Andropin Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
206010003805 Autism Diseases 0.000 description 1
208000020706 Autistic disease Diseases 0.000 description 1
101100013238 Bacillus subtilis (strain 168) folB gene Proteins 0.000 description 1
101100239088 Bacillus subtilis (strain 168) murAA gene Proteins 0.000 description 1
101100131847 Bacillus subtilis (strain 168) murAB gene Proteins 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
108700003860 Bacterial Genes Proteins 0.000 description 1
108020004513 Bacterial RNA Proteins 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
241001105998 Bacteroides dorei Species 0.000 description 1
241000115153 Bacteroides xylanisolvens Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
241001600148 Burkholderiales Species 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
241000605900 Butyrivibrio fibrisolvens Species 0.000 description 1
102000000905 Cadherin Human genes 0.000 description 1
108050007957 Cadherin Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108050004290 Cecropin Proteins 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
206010008096 Cerebral atrophy Diseases 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
UARVBDPGNUHYQT-JXMROGBWSA-N Cinnamyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC\C=C\C1=CC=CC=C1 UARVBDPGNUHYQT-JXMROGBWSA-N 0.000 description 1
SFXQCOMMEMBETJ-KPKJPENVSA-N Cinnamyl phenylacetate Chemical compound C=1C=CC=CC=1/C=C/COC(=O)CC1=CC=CC=C1 SFXQCOMMEMBETJ-KPKJPENVSA-N 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
238000013382 DNA quantification Methods 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
108010002069 Defensins Proteins 0.000 description 1
102000000541 Defensins Human genes 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
241000605716 Desulfovibrio Species 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
241001143779 Dorea Species 0.000 description 1
101710164770 Drosomycin Proteins 0.000 description 1
101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
244000046038 Ehretia acuminata Species 0.000 description 1
235000009300 Ehretia acuminata Nutrition 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000011426 Enoyl-CoA hydratase Human genes 0.000 description 1
108010023922 Enoyl-CoA hydratase Proteins 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
241001608234 Faecalibacterium Species 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
101100171532 Haloferax volcanii (strain ATCC 29605 / DSM 3757 / JCM 8879 / NBRC 14742 / NCIMB 2012 / VKM B-1768 / DS2) hdrA gene Proteins 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
241001453258 Helicobacter hepaticus Species 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101000982656 Homo sapiens 2-oxoglutarate dehydrogenase, mitochondrial Proteins 0.000 description 1
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
208000033830 Hot Flashes Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102100022338 Integrin alpha-M Human genes 0.000 description 1
102100022297 Integrin alpha-X Human genes 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
FOCMOGKCPPTERB-UHFFFAOYSA-N Isovaleriansaeure-trans-cinnamylester Natural products CC(C)CC(=O)OCC=CC1=CC=CC=C1 FOCMOGKCPPTERB-UHFFFAOYSA-N 0.000 description 1
108030000910 L-aspartate oxidases Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241000186783 Lactobacillus vaginalis Species 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
101100178317 Methylorubrum extorquens (strain ATCC 14718 / DSM 1338 / JCM 2805 / NCIMB 9133 / AM1) folK gene Proteins 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
206010028293 Muscle contractions involuntary Diseases 0.000 description 1
206010049816 Muscle tightness Diseases 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000566145 Otus Species 0.000 description 1
239000012661 PARP inhibitor Substances 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
108010000605 Ribosomal Proteins Proteins 0.000 description 1
FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000194020 Streptococcus thermophilus Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
QIOZLISABUUKJY-UHFFFAOYSA-N Thiobenzamide Chemical class NC(=S)C1=CC=CC=C1 QIOZLISABUUKJY-UHFFFAOYSA-N 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
241000589892 Treponema denticola Species 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
102000006668 UniProt protein families Human genes 0.000 description 1
108020004729 UniProt protein families Proteins 0.000 description 1
206010046298 Upper motor neurone lesion Diseases 0.000 description 1
108091008605 VEGF receptors Proteins 0.000 description 1
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
238000001772 Wald test Methods 0.000 description 1
KLKQSZIWHVEARN-RMKNXTFCSA-N [(e)-3-phenylprop-2-enyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC\C=C\C1=CC=CC=C1 KLKQSZIWHVEARN-RMKNXTFCSA-N 0.000 description 1
FOCMOGKCPPTERB-RMKNXTFCSA-N [(e)-3-phenylprop-2-enyl] 3-methylbutanoate Chemical compound CC(C)CC(=O)OC\C=C\C1=CC=CC=C1 FOCMOGKCPPTERB-RMKNXTFCSA-N 0.000 description 1
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
DWDXPVOFUSZPIT-UHFFFAOYSA-N [S].C1=CC=C2NC=CC2=C1 Chemical class [S].C1=CC=C2NC=CC2=C1 DWDXPVOFUSZPIT-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
210000001642 activated microglia Anatomy 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 1
102000005922 amidase Human genes 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000000386 athletic effect Effects 0.000 description 1
230000037147 athletic performance Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000006741 behavioral dysfunction Effects 0.000 description 1
238000009227 behaviour therapy Methods 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
UARVBDPGNUHYQT-UHFFFAOYSA-N benzoic acid cinnamyl ester Natural products C=1C=CC=CC=1C(=O)OCC=CC1=CC=CC=C1 UARVBDPGNUHYQT-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
235000015895 biscuits Nutrition 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
238000009395 breeding Methods 0.000 description 1
108010025307 buforin II Proteins 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229960003669 carbenicillin Drugs 0.000 description 1
FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
229960005361 cefaclor Drugs 0.000 description 1
MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
229960004041 cefetamet Drugs 0.000 description 1
229960002129 cefixime Drugs 0.000 description 1
OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
229960004682 cefoperazone Drugs 0.000 description 1
GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
229960004755 ceftriaxone Drugs 0.000 description 1
VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 description 1
HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
229940117916 cinnamic aldehyde Drugs 0.000 description 1
WJSDHUCWMSHDCR-VMPITWQZSA-N cinnamyl acetate Natural products CC(=O)OC\C=C\C1=CC=CC=C1 WJSDHUCWMSHDCR-VMPITWQZSA-N 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
210000003703 cisterna magna Anatomy 0.000 description 1
229960002626 clarithromycin Drugs 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229960002227 clindamycin Drugs 0.000 description 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
229960003326 cloxacillin Drugs 0.000 description 1
LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000019771 cognition Effects 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
235000012495 crackers Nutrition 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000013075 data extraction Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000010432 diamond Substances 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
230000009274 differential gene expression Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
101150076598 dnaB gene Proteins 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
229950009041 edaravone Drugs 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
238000002567 electromyography Methods 0.000 description 1
230000027721 electron transport chain Effects 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
229960002549 enoxacin Drugs 0.000 description 1
IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000001973 epigenetic effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
229960000741 erythromycin ethylsuccinate Drugs 0.000 description 1
NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 1
229960004213 erythromycin lactobionate Drugs 0.000 description 1
229960004142 erythromycin stearate Drugs 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000004424 eye movement Effects 0.000 description 1
101150100150 fabI gene Proteins 0.000 description 1
101150092019 fadJ gene Proteins 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
230000010006 flight Effects 0.000 description 1
229940124307 fluoroquinolone Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
101150064419 folA gene Proteins 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000010437 gem Substances 0.000 description 1
238000012268 genome sequencing Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000004383 glucosinolate group Chemical group 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
235000011868 grain product Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000009499 grossing Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
229920000591 gum Polymers 0.000 description 1
101150013736 gyrB gene Proteins 0.000 description 1
230000004886 head movement Effects 0.000 description 1
230000007407 health benefit Effects 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
238000012165 high-throughput sequencing Methods 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229960002182 imipenem Drugs 0.000 description 1
GSOSVVULSKVSLQ-JJVRHELESA-N imipenem hydrate Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 1
230000009390 immune abnormality Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
210000005027 intestinal barrier Anatomy 0.000 description 1
230000007358 intestinal barrier function Effects 0.000 description 1
210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229930013032 isoflavonoid Natural products 0.000 description 1
150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
235000012891 isoflavonoids Nutrition 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229940035901 lactobacillus sp Drugs 0.000 description 1
238000005339 levitation Methods 0.000 description 1
229920005610 lignin Polymers 0.000 description 1
229940041028 lincosamides Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
238000011551 log transformation method Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
235000013622 meat product Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
101150106833 metG gene Proteins 0.000 description 1
101150062025 metG1 gene Proteins 0.000 description 1
230000004066 metabolic change Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960000198 mezlocillin Drugs 0.000 description 1
YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
238000010208 microarray analysis Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000037230 mobility Effects 0.000 description 1
230000004879 molecular function Effects 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000009343 monoculture Methods 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
101150025333 murA gene Proteins 0.000 description 1
101150023205 murA1 gene Proteins 0.000 description 1
101150089003 murA2 gene Proteins 0.000 description 1
230000020763 muscle atrophy Effects 0.000 description 1
238000001964 muscle biopsy Methods 0.000 description 1
201000000585 muscular atrophy Diseases 0.000 description 1
230000023105 myelination Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
229960000515 nafcillin Drugs 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
238000002610 neuroimaging Methods 0.000 description 1
230000004693 neuron damage Effects 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
230000006764 neuronal dysfunction Effects 0.000 description 1
230000006576 neuronal survival Effects 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
238000007481 next generation sequencing Methods 0.000 description 1
229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
235000020956 nicotinamide riboside Nutrition 0.000 description 1
239000011618 nicotinamide riboside Substances 0.000 description 1
JOUIQRNQJGXQDC-ZYUZMQFOSA-L nicotinate D-ribonucleotide(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1[N+]1=CC=CC(C([O-])=O)=C1 JOUIQRNQJGXQDC-ZYUZMQFOSA-L 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000001937 non-anti-biotic effect Effects 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
108010067588 nucleotide pyrophosphatase Proteins 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
229960001019 oxacillin Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
230000036284 oxygen consumption Effects 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
101150012629 parE gene Proteins 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
230000004108 pentose phosphate pathway Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
238000002205 phenol-chloroform extraction Methods 0.000 description 1
229930015704 phenylpropanoid Natural products 0.000 description 1
125000001474 phenylpropanoid group Chemical group 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000005097 photorespiration Effects 0.000 description 1
230000029553 photosynthesis Effects 0.000 description 1
238000010672 photosynthesis Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960002292 piperacillin Drugs 0.000 description 1
WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
238000013439 planning Methods 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229930001119 polyketide Natural products 0.000 description 1
125000000830 polyketide group Chemical group 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
238000007781 pre-processing Methods 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
229930010796 primary metabolite Natural products 0.000 description 1
230000037452 priming Effects 0.000 description 1
201000002241 progressive bulbar palsy Diseases 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
101150046246 pytH gene Proteins 0.000 description 1
210000003314 quadriceps muscle Anatomy 0.000 description 1
238000004451 qualitative analysis Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
150000007660 quinolones Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000030100 regulation of tryptophan metabolic process Effects 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
230000035806 respiratory chain Effects 0.000 description 1
230000036387 respiratory rate Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
108020004418 ribosomal RNA Proteins 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
229960004181 riluzole Drugs 0.000 description 1
239000005060 rubber Substances 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
238000001963 scanning near-field photolithography Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
229930000044 secondary metabolite Natural products 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000007841 sequencing by ligation Methods 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
238000010008 shearing Methods 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000011888 snacks Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
PNFSYNAUAPBVGF-UHFFFAOYSA-M sodium;phenyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=CC=C1 PNFSYNAUAPBVGF-UHFFFAOYSA-M 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
230000035882 stress Effects 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
238000001847 surface plasmon resonance imaging Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000003956 synaptic plasticity Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012353 t test Methods 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229960003865 tazobactam Drugs 0.000 description 1
LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960004659 ticarcillin Drugs 0.000 description 1
OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
229960000707 tobramycin Drugs 0.000 description 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000012384 transportation and delivery Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
101150099542 tuf gene Proteins 0.000 description 1
101150071165 tuf1 gene Proteins 0.000 description 1
101150010742 tuf2 gene Proteins 0.000 description 1
101150061352 tufA gene Proteins 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
238000004704 ultra performance liquid chromatography Methods 0.000 description 1
229910021642 ultra pure water Inorganic materials 0.000 description 1
239000012498 ultrapure water Substances 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000004143 urea cycle Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000010603 vasculitis due to ADA2 deficiency Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
229950011257 veliparib Drugs 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
238000012070 whole genome sequencing analysis Methods 0.000 description 1